Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKJIDU)

• Drug Name: TZI-41078 Drug Info
• Synonyms: 3,5-Di-tert-butyl-4-hydroxybenzophenone oxime

Indication

Disease Entry	ICD 11	Status	REF
Arthritis	FA20	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 136393672
  TTD Drug ID: DMKJIDU

Molecule-Related Drug Atlas

Drug(s) Targeting Prostaglandin G/H synthase (COX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[2]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[3]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[4]
Dexibuprofen	DMFYBD0	Ankylosing spondylitis	FA92.0	Approved	[5]
Ketorolac	DMI4EL5	Postoperative inflammation	1A00-CA43.1	Approved	[6]
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[7]
Oxaprozin	DM9UB0P	Osteoarthritis	FA00-FA05	Approved	[8]
Aceclofenac	DMZDF0B	Inflammation	1A00-CA43.1	Approved	[9]
Lornoxicam	DMYZFXN	Migraine	8A80	Approved	[10]
Morniflumate	DM9UTDE	Otitis media	AA80-AB0Z	Approved	[11]

Drug(s) Targeting Lipoxygenase (ALOX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CPA-926	DMH5LKS	Arthritis	FA20	Discontinued in Phase 2	[12]
FLM-5011	DMKWTPX	Inflammation	1A00-CA43.1	Discontinued in Phase 1	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Lipoxygenase (ALOX)	TTG3K2U	NOUNIPROTAC	Modulator	[1]
Prostaglandin G/H synthase (COX)	TTK0943	PGH1_HUMAN; PGH2_HUMAN	Modulator	[1]

References

• [1] Hydroxylamine analogs of 2,6-di-t-butylphenols: dual inhibitors of cyclooxygenase and 5-lipoxygenase or selective 5-lipoxygenase inhibitors. Bioorg Med Chem. 1995 Apr;3(4):403-10.
• [2] Mechanism of action of paracetamol. Am J Ther. 2005 Jan-Feb;12(1):46-55.
• [3] Diclofenac and NS-398, a selective cyclooxygenase-2 inhibitor, decrease agonist-induced contractions of the pig isolated ureter. Urol Res. 2000 Dec;28(6):376-82.
• [4] Cyclooxygenase inhibitors: instrumental drugs to understand cardiovascular homeostasis and arterial thrombosis. Cardiovasc Hematol Disord Drug Targets. 2008 Dec;8(4):268-77.
• [5] Comparison of the efficacy and tolerability of dexibuprofen and celecoxib in the treatment of osteoarthritis of the hip. Int J Clin Pharmacol Ther. 2003 Apr;41(4):153-64.
• [6] Cyclooxygenase and nitric oxide synthase dependence of cutaneous reactive hyperemia in humans. Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H425-32.
• [7] Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann N Y Acad Sci. 1994 Nov 15;744:50-7.
• [8] The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer Res. 2007 Apr 1;67(7):3254-62.
• [9] Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther. 2003 Sep;74(3):222-35.
• [10] The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79.
• [11] Modulation of arachidonic acid metabolism by orally administered morniflumate in man. Agents Actions. 1991 Jul;33(3-4):233-9.
• [12] Esculetin (dihydroxycoumarin) inhibits the production of matrix metalloproteinases in cartilage explants, and oral administration of its prodrug, CPA-926, suppresses cartilage destruction in rabbit experimental osteoarthritis. J Rheumatol. 1999 Mar;26(3):654-62.
• [13] Lipoxygenase inhibitor FLM 5011, an effective protectant of myocardial microvessels against ischemia-reperfusion injury. Exp Toxicol Pathol. 2000 Mar;52(1):27-36.